Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)

The National Cancer Institute (NCI) is offering an Innovative Research in Cancer Nanotechnology grant (IRCN). The notice for this funding opportunity (NOFO) encourages applications that aim to foster substantial advancements in cancer biology and oncology through the utilization of nanotechnology. The suggested projects should focus on overcoming significant obstacles in these fields with the aid of nanotechnology, placing emphasis on the mechanistic examination that aspires to gain a deeper, fundamental insight into how nanomaterials and nanodevices interact with various biological systems.

The research should be conducted concerning the delivery of nanoparticles and nano-devices to specified, intended cancer targets within a living organism (in vivo) or the characterization of detection and diagnostic devices in a controlled environment (in vitro). The purpose of the IRCN grant is to assist the generation of essential knowledge, with the expectation of fostering more insightful future development of nanotechnology-based cancer interventions. However, the process of transferring these interventions from the lab to the patient (clinical translation) does not fall under the scope of this funding opportunity.